ClinicalTrials.gg
CompletedNCT04772885Updated Oct 24, 2022

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

A Phase 1 interventional study of KT-474/Placebo and KT-474 in Healthy Volunteer, Atopic Dermatitis and Hidradenitis Suppurativa, sponsored by Kymera Therapeutics, Inc.. Completed at 14 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-24.

Sponsored by Kymera Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2022, 4 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
206th of 544
154 · median 96
Started
2021
with 47 others
Phase 1
82 of 639
10 open now
Registered
404th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 206th largest by enrollment of the 544 interventional ones that give a count, is one of 48 that started in 2021, is one of 82 in phase 1, and was the 404th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases. This first-in-human (FIH) study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of KT-474 in healthy volunteers and patients with atopic dermatitis (AD) or hidradenitis suppurativa (HS). The effects of food on the absorption of KT-474 will also be evaluated in healthy volunteers.

Read the detailed description

This is a first-in-human (FIH), Phase 1 randomized, placebo-controlled, single and multiple ascending dose trial of KT-474 that will characterize the safety, PK and PD of orally administered KT-474 after a single dose (Part A) and after repeated dosing first in healthy adult volunteers (Part B) and then in patients with AD or HS (Part C). Initially, a dose range of KT-474 in single ascending dose (SAD) escalation cohorts will be explored in healthy subjects. Up to five single dose cohorts of healthy subjects is also planned to understand food effects (FE) on the PK of KT-474. Enrollment of healthy subjects into 2-week multiple ascending dose (MAD) escalation cohorts will be initiated once sufficient safety and PK data from multiple SAD cohorts are available to inform the safe starting dose for the 2-week MAD portion of the study. After the MAD portion in healthy subjects is completed, the safety, PK, and PD of a dose of KT-474 that was found to be safe in healthy subjects when administered for 2 weeks will then be evaluated in AD or HS subjects for 28 days of dosing. Separately, additional multiple dose cohorts evaluating once every other day and/or twice weekly dosing schedules at or below previously evaluated dose levels in healthy volunteers may be initiated.

03

Conditions studied

  • Healthy Volunteer
  • Atopic Dermatitis
  • Hidradenitis Suppurativa

Keywords

  • Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Immune-inflammatory diseases
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Healthy Volunteer (Parts A and B) Inclusion Criteria:

  1. Male and female subjects, including female subjects of child bearing potential, between the ages of 18 and 55 with a weight at least 50 kg and a (BMI) between 18.0 and 30.0 kg/m2.
  2. Subjects confirmed as negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection test at Screening and on Day -2.
  3. Evidence of a personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study.
  4. Agreement and ability to comply with all requirements if applicable.
  5. All subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Healthy Volunteer (Parts A and B) Exclusion Criteria:

  1. Evidence or history of a medical condition or other condition that might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study.
  2. Healthy volunteers who have a clinically relevant history or presence of respiratory, GI, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, or connective tissue diseases or disorders.
  3. Healthy volunteers who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.
  4. Female Healthy volunteers who are pregnant, trying to become pregnant or lactating or breastfeeding.
  5. Healthy volunteers who have participated in any drug or device clinical study within 3 months prior to first dosing on this study.
  6. Healthy volunteers who have previously participated in a study with an investigational product or device involving the dosing of a biological targeted at any immune pathway within 1 year prior to Screening.

AD or HS Patient (Part C) Inclusion Criteria:

  1. Male or female patients aged 18 years to 55 years (inclusive) at the time of Screening, and in generally good health, except for AD or HS, and has a BMI of 17.5 to 35.0 kg/m2; and a total body weight >50 kg (110 lb).
  2. Diagnosis of AD or HS for at least 6 months.
  3. Patients with AD: having at least 10% treatable percentage body surface area at Screening or on Admission (excluding the scalp and designated venous access areas).
  4. Willingness and ability to comply with all contraception requirements as applicable based on reproductive status.
  5. Has adequate venous access with venous access sites having AD-unaffected, non-infected skin to permit repeated PK sampling.
  6. Female patients must have a negative result for the serum pregnancy test at the Screening Visit and on admission.
  7. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
  8. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  9. Patients with HS: A total Abscess and Inflammatory Nodule count of ≥4 at baseline

AD or HS Patient (Parts C) Exclusion Criteria:

  1. Has any clinically significant medical disorder, condition, disease (including active or potentially recurrent dermatological conditions other than AD or HS), significant physical examination or laboratory findings that may interfere with study objectives, in the Investigator's opinion (eg, conditions or findings that may expose a patient to unacceptable risk by study participation, confound the evaluation of treatment response or adverse events, or otherwise interfere with a patient's ability to complete the study).
  2. Has an active systemic or soft tissue infection, including known actively-infected AD or HS skin lesion.
  3. Treatment with an investigational product within 30 days or 5 half-lives preceding the first dose of investigational product (whichever is longer).
  4. Use of prescription or nonprescription drugs including topical , vitaminic and dietary supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
  5. Blood donation (excluding plasma donations and donations) of approximately ≥400 mL within 3 months or ≥200 mL within a month prior to dosing.
  6. History of sensitivity to heparin or heparin-induced thrombocytopenia.
  7. Unwilling or unable to comply with the protocol procedures and/or assessments.
  8. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
  9. Patients with HS: Fistula and Tunnel count of >20 at baseline.
  10. Patients with AD: Active herpes infection or history of eczema herpeticum.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Single ascending dose cohorts in healthy subjects

    Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of KT-474 or placebo. The first cohort will receive 25 mg of KT-474 or placebo. Dose escalation will occur if KT-474 or placebo is tolerated.

    Drug: KT-474/Placebo

  • Experimental
    Multiple ascending dose cohorts in healthy subjects

    Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo for 14 days continuous dosing. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD portion.

    Drug: KT-474/Placebo

  • Experimental
    Food Effect Cohort in healthy subjects

    Healthy Volunteer SAD subject cohorts (up to 5) will receive a single dose of KT-474 in the fed state.

    Drug: KT-474/Placebo

  • Experimental
    Multiple dose cohort in HS and AD patients

    A single cohort of up to 30 patients with AD or HS to receive a dose of KT-474 determined to be safe based on data generated in the healthy volunteer MAD portion, dosed daily X 28 days.

    Drug: KT-474

  • Experimental
    Multiple dose cohorts in healthy subjects

    Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo every other day over 14 days, and/or twice weekly over 15 days. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD and MAD portion.

    Drug: KT-474/Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment emergent Adverse Events

    Time frame: up to 28 days

  2. Incidence and frequency of use of concomitant medication

    Time frame: up to 28 days

Secondary outcomes

  1. Area under the curve plasma concentration from time zero to infinity [AUC(0-∞)] (single dose only)

    Time frame: up to 28 days

  2. Area under the curve plasma concentration from time zero to last measurable concentration [AUC(0-last)]

    Time frame: up to 28 days

  3. Area under the plasma concentration-time curve during a dosing interval [AUC(0-tau)]

    Time frame: up to 28 days

  4. Maximum observed plasma concentration (Cmax)

    Time frame: up to 28 days

  5. Time to maximum observed plasma concentration (Tmax)

    Time frame: up to 28 days

  6. Apparent clearance (CL/F)

    Time frame: up to 28 days

  7. Apparent volume of distribution (Vz/F)

    Time frame: up to 28 days

  8. Terminal elimination half-life (t1/2)

    Time frame: up to 28 days

  9. Mean residence time (MRT)

    Time frame: up to 28 days

  10. Renal clearance (CLR)

    Time frame: up to 28 days

Other outcomes

  1. IRAK4 levels in peripheral blood mononuclear cells

    Time frame: up to 28 days

  2. IRAK4 levels in skin

    Time frame: up to 28 days

  3. Percentage Change from baseline in Total Abscess and Inflammatory Nodule (AN) Count, Skin Pain Numerical Rating Scale (NRS), Peak pruritis NRS, and HS Physician's Global Assessment (HS-PGA) in HS patients

    Time frame: up to 42 days

  4. Percentage Change from baseline in Eczema Area and Severity Index (EASI), Peak Pruritus Numerical Rating Scale (NRS) and Investigator Global Assessment (IGA) in AD patients

    Time frame: up to 42 days

07

Study locations

14 sites
  • Medical Dermatology Specialists
    Phoenix, Arizona 85006, United States
  • Southwest Skin Specialists 32nd St
    Phoenix, Arizona 85018, United States
  • Southwest Skin Specialists Tatum
    Phoenix, Arizona 85028, United States
  • Beatrice Keller Clinic
    Sun City West, Arizona 85375, United States
  • Encore Medical Research, LLC. - Boynton Beach
    Boynton Beach, Florida 33436, United States
  • Research Centers of America
    Hollywood, Florida 22024, United States
  • Encore Medical Research, LLC. - Hollywood
    Hollywood, Florida 33021, United States
  • Encore Medical Research, LLC. - Weston
    Weston, Florida 33331, United States
  • Dermatology and Skin Cancer Center of Leawood
    Leawood, Kansas 66211, United States
  • Dermatology and Skin Cancer Center of Overland Park
    Overland Park, Kansas 66223, United States
  • Dermatology and Skin Cancer Center of Lee's Summit
    Lee's Summit, Missouri 64064, United States
  • TKL Research
    Fair Lawn, New Jersey 07410, United States
  • U.S. Dermatology Partners Jollyville
    Austin, Texas 78759, United States
  • U.S. Dermatology Partners Cedar Park
    Cedar Park, Texas 78613, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Oct 2022, 19 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 19 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2021
First posted
Feb 26, 2021
StartActual
Feb 23, 2021
Primary completionActual
Oct 20, 2022
CompletionActual
Oct 20, 2022
Last update
Oct 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04772885
Lead sponsor
Kymera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
Feb 23, 2021
Primary completion
Oct 20, 2022
Completion
Oct 20, 2022
Last update
Oct 24, 2022

Study contacts

Ashwin Gollerkeri, MD
study director · Kymera Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tipasertideg

Start the discussion